>Marché mondial des troubles de la vessie, par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle, cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire , autres), canal de distribution (direct, vente au détail) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché des troubles de la vessie
Les troubles de la vessie sont un groupe de troubles qui peuvent affecter les activités quotidiennes de la vie humaine. Certains des troubles de la vessie les plus courants sont la cystite, dans laquelle la vessie est infectée et provoque une inflammation. L'incontinence urinaire, dans laquelle la vessie est perdue, la cystite interstitielle , qui provoque des douleurs à la vessie et des mictions fréquentes et urgentes, et la vessie hyperactive , une condition dans laquelle la vessie comprime l'urine. Les troubles de la vessie peuvent affecter la qualité de vie et causer d'autres problèmes de santé. Les changements et problèmes de santé, notamment les facteurs liés au système nerveux et au mode de vie, peuvent provoquer ou contribuer à l'IU chez les hommes et les femmes.
Les troubles de la vessie les plus courants sont l'hyperactivité vésicale et l'incontinence urinaire. Ces problèmes sont associés au système nerveux. Les nerfs transmettent des messages du cerveau à la vessie, indiquant que les muscles se contractent ou se relâchent.
Le marché mondial des troubles de la vessie devrait croître au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 11,4 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 22 342,48 millions USD d'ici 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (Personnalisable 2019-2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle, cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire, autres), canal de distribution (direct, vente au détail) |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, Royaume-Uni, France, Italie, Espagne, Turquie, Russie, Pays-Bas, Suisse, Belgique et reste de l'Europe, Chine, Japon, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Vietnam, Reste de l'Asie-Pacifique, Brésil, Argentine, Pérou, Reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël, Reste du Moyen-Orient et Afrique |
|
Acteurs du marché couverts |
Français Les principales entreprises présentes sur le marché sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences entre autres. |
Définition du marché mondial des troubles de la vessie
Les troubles liés à la vessie comprennent la cystite (inflammation de la vessie, souvent due à une infection), l'incontinence urinaire (perte de contrôle de la vessie), l'hyperactivité vésicale (une condition dans laquelle la vessie expulse l'urine au mauvais moment), la cystite interstitielle (un problème chronique qui provoque des douleurs à la vessie et des mictions fréquentes et urgentes) et le cancer de la vessie.
Différents tests sont effectués par les médecins pour diagnostiquer le trouble de la vessie, notamment des radiographies, des analyses d'urine et un examen de la paroi de la vessie à l'aide d'un appareil appelé cystoscope. Le traitement du trouble dépend de la cause du problème et comprend des médicaments, des interventions chirurgicales (dans les cas graves) et des procédures non chirurgicales.
Les médicaments anticholinergiques constituent la première ligne de traitement pharmacologique du syndrome de la vessie hyperactive (VHA). La VHA est un symptôme clinique caractérisé par une envie impérieuse d'uriner, qui est difficile à différer. En général, une fréquence d'uriner supérieure à huit fois par jour est considérée comme une VHA. Les médicaments anticholinergiques inhibent les récepteurs muscariniques du muscle détrusor qui réduisent la contractilité de la vessie. Pour réduire les effets secondaires, de nouveaux médicaments avec une sélectivité vésicale améliorée et des formulations à libération prolongée sont en cours de développement. La majorité des médicaments les plus récents sont tout aussi efficaces pour réduire les symptômes d'une vessie hyperactive.
Dynamique du marché mondial des troubles de la vessie
Conducteurs
-
INITIATIVES STRATÉGIQUES ADOPTÉES PAR LES ACTEURS DU MARCHÉ
Les troubles de la vessie sont un ensemble de problèmes de vessie qui peuvent affecter les activités physiques quotidiennes. Les troubles de la vessie les plus courants sont la cystite, la cystite interstitielle, l'hyperactivité vésicale, l'incontinence urinaire et le cancer de la vessie. La plupart des problèmes de vessie sont causés par une infection bactérienne qui pénètre dans les voies urinaires.
Diverses initiatives stratégiques des acteurs du marché en termes de collaboration, d'acquisition, de partenariat et autres, leur permettent d'augmenter le portefeuille de produits de leur entreprise, conduisant à l'expansion du marché et donc à l'amélioration de la demande de produits parmi les clients, ce qui permet finalement aux acteurs du marché de gagner un maximum de revenus.
-
POPULATION GÉRIATRIQUE CROISSANTE
Le vieillissement est un facteur de risque important qui peut être associé aux troubles liés à la vessie. Le vieillissement entraîne des changements neurologiques, anatomiques et biochimiques dans la fonction de la vessie, ce qui peut entraîner le développement d'une vessie hyperactive. L'hyperactivité vésicale est le problème le plus courant chez la population gériatrique. La population vieillissante souffre de divers problèmes et troubles associés à la vessie en raison desquels elle est la principale utilisatrice de services et de solutions de gestion de la santé chronique.
Selon l'étude Noble, le taux de prévalence de la vessie hyperactive est d'environ 16,9 chez les femmes et les hommes, soit environ 16,0 %, et la prévalence de l'HVV augmente avec l'âge. Cependant, les directives de traitement précisent les stratégies thérapeutiques préférées de première, deuxième et troisième intention pour l'HVV. Les troubles de la vessie sont associés à des troubles neurologiques tels que la démence, et dans ce groupe d'âge, l'HVV est un véritable défi pour la population âgée. Au cours des dernières décennies, la population âgée a connu une croissance spectaculaire dans le monde entier.
-
AUGMENTATION DES INVESTISSEMENTS EN R&D ET LANCEMENT DE NOUVELLES THÉRAPIES DANS LES ANNÉES À VENIR
Il existe plusieurs options de traitement et thérapies innovantes pour l'HVV et d'autres troubles de la vessie. De nombreuses sociétés biopharmaceutiques et pharmaceutiques investissent dans diverses thérapies non conventionnelles pour les troubles de la vessie, qui devraient être lancées au cours de la période de prévision.
-
COMBINAISON DE DIFFÉRENTES THÉRAPIES CIBLÉES
Les thérapies combinées sont beaucoup plus efficaces que la monothérapie, sans effets secondaires supplémentaires. Les thérapies combinées sont une alternative sûre et efficace pour les personnes souffrant de troubles réfractaires de la vessie. La combinaison de différentes stratégies de thérapie ciblée est la meilleure approche pour soulager les patients atteints de troubles de la vessie. Des médicaments oraux et une thérapie comportementale doivent être envisagés pour le traitement réfractaire des patients. Diverses thérapies ciblées avancées sont disponibles, telles que la neuromodulation sacrée, l'injection intradétrusorienne de toxine botulique A et la stimulation percutanée du nerf tibial. Il s'agit de traitements avancés et plus efficaces que les agents oraux.
Opportunités
-
HAUSSE DES NOUVELLES AVANCÉES TECHNOLOGIQUES
Les maladies chroniques sont considérées comme l’une des principales causes de décès dans les pays en développement. Par conséquent, l’importance de la gestion des maladies chroniques dans les soins de santé est de plus en plus importante parmi les praticiens de la santé publique.
La prise en charge des troubles de la vessie met désormais l’accent sur l’aide aux patients en leur proposant une gamme d’alternatives pour prendre soin d’eux-mêmes et une gamme de services de consultation pour les informer sur leur état de santé et aller de l’avant. Ces thérapies aident également les patients à surmonter les traumatismes émotionnels et l’anxiété, qui peuvent agir comme un mécanisme de contre-protection.
Les avancées technologiques croissantes permettent aux organisations de soins de santé d'explorer des services et des solutions innovants pour la gestion des troubles chroniques de la vessie. Comme ils ne sont pas obligés de rester à l'hôpital pendant une période prolongée, ils ont également réduit les coûts et le volume de patients. De plus, la réduction des visites et des séjours à l'hôpital rend ce développement pratique pour les personnes âgées. Compte tenu des aspects favorables, de nombreuses organisations et entreprises développent et mettent en œuvre les technologies les plus récentes dans la gestion des maladies chroniques pour améliorer les résultats des patients.
-
PROGRAMMES DE GESTION DES MALADIES EN HAUSSE
People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.
Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.
Restraints/Challenges
However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.
This bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Global Bladder Disorders Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market
Recent Development
- In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio
Global Bladder Disorders Market Scope
Global bladder disorders market is segmented into treatment, end user, and distribution channel types. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Cystitis
- Urinary Incontinence
- Overactive Bladder
- Interstitial Cystitis
- Bladder Cancer
On the basis of type, the global bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, bladder cancer.
Treatment type
- Surgery
- Medications
- Others
On the basis of product, the global bladder disorders market is segmented into surgery, medication, and others.
End User
- Hospital
- Clinics
- Ambulatory Surgery centers
- Others
On the basis of end users, the global bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others.
Distribution Channel
- Direct
- Retail
On the basis of distribution channel, the global bladder disorders market is segmented into direct and retail.
Global Bladder Disorders Market Regional Analysis/Insights
The global bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.
Countries covered in this market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.
North America dominates the global bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Les points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales des troubles de la vessie
Le paysage concurrentiel du marché mondial des troubles de la vessie fournit des détails sur les concurrents. Les détails comprennent un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que l'orientation de l'entreprise vers le marché mondial des troubles de la vessie.
Français Certains des principaux acteurs opérant sur le marché mondial des troubles de la vessie sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale et régionale et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 GLOBAL BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 GLOBAL BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 GLOBAL BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 GLOBAL BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 GLOBAL BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 GLOBAL BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 TURKEY
11.3.7 RUSSIA
11.3.8 NETHERLANDS
11.3.9 SWITZERLAND
11.3.10 BELGIUM
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 THAILAND
11.4.7 SINGAPORE
11.4.8 INDONESIA
11.4.9 MALAYSIA
11.4.10 VIETNAM
11.4.11 PHILIPPINES
11.4.12 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SAUDI ARABIA
11.6.2 SOUTH AFRICA
11.6.3 UAE
11.6.4 EGYPT
11.6.5 ISRAEL
11.6.6 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 U.S. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 U.S. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 U.S. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 U.S. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 U.S. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 35 U.S. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 CANADA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 CANADA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 CANADA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CANADA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MEXICO BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MEXICO BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 MEXICO MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 MEXICO SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 MEXICO BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 MEXICO BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 59 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 61 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 72 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 73 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 79 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 82 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 87 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 99 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 100 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 101 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 102 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 103 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 108 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 111 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 112 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 113 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 115 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 117 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 119 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 125 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 126 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 127 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 129 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 131 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 133 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 143 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 145 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 146 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 147 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 149 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 150 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 151 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 155 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 156 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 158 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 159 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 161 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 163 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 169 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 170 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 171 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 173 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 175 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 179 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 181 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 183 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 186 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 187 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 188 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 SOUTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 191 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 193 SOUTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 194 SOUTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 195 SOUTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 SOUTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 BRAZIL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 BRAZIL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 199 BRAZIL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 200 BRAZIL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 201 BRAZIL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 202 BRAZIL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 203 ARGENTINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 ARGENTINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 205 ARGENTINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 206 ARGENTINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 207 ARGENTINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 ARGENTINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 209 REST OF SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 214 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 215 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 216 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 217 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 219 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 220 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 221 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 225 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 226 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 227 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 231 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 232 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 233 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 234 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 235 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 237 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 238 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 239 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 240 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 241 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 243 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 244 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 245 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 GLOBAL BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BLADDER DISORDERS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE GLOBAL BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER DISORDERS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR BLADDER DISORDERS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER DISORDER MARKET
FIGURE 16 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 17 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 21 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 22 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 23 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 29 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 GLOBAL BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 GLOBAL BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 33 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021)
FIGURE 34 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2022 & 2029)
FIGURE 35 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021 & 2029)
FIGURE 36 GLOBAL BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 37 NORTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 38 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 39 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 NORTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 42 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 47 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 48 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 49 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 52 SOUTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 53 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 54 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 55 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 56 SOUTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 57 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 58 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 59 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 60 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 61 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 62 GLOBAL BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 63 NORTH AMERICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 65 ASIA-PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
